Atea Completes Enrollment in C-BEYOND Hepatitis C Trial: Mid-2026 Data Expected

Atea Pharmaceuticals has completed enrollment in its Phase 3 trial, C-BEYOND, for its hepatitis C treatment. The trial compares the company's Bemnifosbuvir and Ruzasvir regimen to a standard of care. Topline results are expected in mid-2026, and the company has sufficient cash to fund its ongoing clinical programs. The trial is significant as it is the first to directly compare investigational direct-acting antivirals against established regimens.